In this new collaboration, BioFocus DPI will provide assay development and high-throughput screening services for several Allergan targets. Furthermore, BioFocus DPI’s computational chemists plan to work together with Allergan to select compounds from the Allergan and BioFocus DPI compound libraries for screening against these targets.
Onno van de Stolpe, CEO of Galapagos, said: “We are pleased to sign another collaboration with Allergan. They are an important customer for BioFocus DPI’s biology business and having a satisfied customer coming back for more screening is gratifying.”